Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study

Matthias Büttner(Johannes Gutenberg University Mainz), Martin Eichler(National Center for Tumor Diseases), Susanne Singer(Jagiellonian University), Martin Bornhäuser(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Daniel Pink(Universitätsmedizin Greifswald), Peter Hohenberger(Centre Oscar Lambret), Markus K. Schuler(University Hospital Carl Gustav Carus), Stephan Richter(University Hospital Carl Gustav Carus), Leopold Hentschel(National Center for Tumor Diseases), Jochen Schmitt(University Hospital Carl Gustav Carus), Bernd Kasper(Heidelberg University), Kathy Taylor(Johannes Gutenberg University Mainz), Dimosthenis Andreou(University Hospital Münster), Karin Arndt
Supportive Care in Cancer
July 11, 2021
10.1007/s00520-021-06406-3
Cited by 27

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978